Welcome to our dedicated page for BridgeBio Oncology Therapeutics news (Ticker: BBOT), a resource for investors and traders seeking the latest updates and insights on BridgeBio Oncology Therapeutics stock.
BridgeBio Oncology Therapeutics, Inc. develops clinical-stage oncology therapeutics focused on RAS-pathway malignancies and cancers driven by RAS and PI3Kα biology. Company news centers on small-molecule pipeline updates, including BBO-11818, a selective oral pan-KRAS inhibitor, and BBO-10203, a RAS:PI3Kα breaker designed to disrupt oncogenic signaling.
Recurring updates include preclinical and clinical data presentations, oncology conference disclosures, FDA regulatory designations, publication of research data, inducement equity grants, and governance changes. BBOT also reports operating and financial results tied to development-stage biotechnology activities.
BBOT (Nasdaq: BBOT) reported first quarter 2026 results and key RAS-pathway oncology updates. Three Phase 1 programs showed encouraging preliminary safety and efficacy, including a 65% ORR and 68% 6‑month PFS for BBO-8520 in KRASG12C NSCLC and a 56% tumor reduction PR for BBO-11818 in PDAC.
For the quarter, BBOT reported a net loss of $42.1 million, with R&D expenses of $39.8 million and G&A expenses of $6.4 million. Cash, cash equivalents and marketable securities totaled $388.9 million, expected to fund operations into 2028. Multiple clinical readouts are anticipated in the second half of 2026.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) granted inducement stock options under its 2025 Inducement Plan on May 10, 2026. One new employee received options for 32,675 shares at an exercise price of $7.66 per share, vesting over four years, under Nasdaq Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) presented preclinical data on BBO-11818 at AACR 2026 showing an orally bioavailable, non-covalent pan-KRAS inhibitor that targets mutant KRAS in both ON (GTP-bound) and OFF (GDP-bound) states. The poster reports potent MAPK/ERK suppression, anti-proliferative activity, monotherapy tumor regressions, and enhanced efficacy in combinations across KRASG12D and KRASG12V models. Combination partners included BBO-10203, cetuximab, and anti-PD-1; complete regressions and an adaptive immune response were reported in the CT26 syngeneic model. Updated Phase 1 clinical data are expected in the second half of 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced leadership changes effective April 20, 2026: Pedro J. Beltran, PhD named CEO, Idan Elmelech named COO, and Neil Kumar, PhD appointed Executive Chairman. The transition accompanies Phase 1b expansions and combination studies across RAS and PI3Kα malignancies.
Former CEO Eli Wallace, PhD, will remain as Senior Adviser to support ongoing programs and continuity.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) presented preclinical data for BBO-10203 at AACR Annual Meeting 2026 showing the RAS:PI3Kα breaker physically and allosterically disrupts RAS–PI3Kα interaction, inhibiting PI3Kα–AKT signaling.
Key findings: tumor regressions at 30 mg/kg QD, no hyperglycemia observed at 100 mg/kg QD, activity independent of RAS/PI3Kα mutational status, and strong in vivo combination activity with tucatinib and trastuzumab. Updated clinical data expected H2 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced the U.S. FDA has granted Fast Track designation to BBO-11818 for treating adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma on April 20, 2026.
BBO-11818 is a pan-KRAS inhibitor in a Phase 1 trial (KONQUER-101); preliminary January 2026 data showed a confirmed partial response in pancreatic cancer and dose-dependent tumor reductions. Updated Phase 1 data expected in the second half of 2026.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) awarded inducement grants on April 10, 2026 under its 2025 Inducement Plan to a new hire from March 2026. The company granted non-qualified stock options for 32,675 shares at an exercise price of $8.40 per share, equal to Nasdaq closing price on the grant date.
The options vest 25% on the first anniversary of the employee's start date and then in 36 equal monthly installments, subject to continued service. The grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, April 17-22 in San Diego.
BBOT will present an oral session on BBO-10203 inhibiting PI3Kα/AKT via non-canonical RAS signaling on April 21, and a poster on BBO-11818 KRAS inhibitors on April 22.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced publication in Cancer Discovery of preclinical data for BBO-11818, a non‑covalent, orally bioavailable panKRAS inhibitor that binds KRAS in both ON and OFF states and shows activity across KRASG12D, G12V, and G12C mutants.
Key facts: >500‑fold selectivity for KRAS over other RAS isoforms, robust monotherapy tumor inhibition in preclinical models across colorectal, pancreatic, and lung cancers, and a confirmed partial response (56% tumor reduction) in the ongoing Phase 1 KONQUER‑101 trial. Additional clinical data and an internal combination with BBO‑10203 are expected later in 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported Q4 and full‑year 2025 results and clinical progress on three RAS‑pathway programs. Key points: $425.5M cash runway into 2028, encouraging preliminary clinical signals for BBO‑8520, BBO‑11818 and BBO‑10203, and multiple data readouts expected in H2 2026.
Financials show elevated R&D spend and wider net losses as BBOT advances trials and began standalone public operations after its August 2025 de‑SPAC.